There is no cure for Alzheimer’s disease. No treatment can reverse the damage it causes or stop it entirely. But the treatment landscape has shifted significantly in recent years, with the first drugs that actually slow the disease’s progression now available. That’s a meaningful change from decades of medications that only managed symptoms without touching the underlying biology.
What Today’s Treatments Can and Can’t Do
For most of Alzheimer’s treatment history, the only options were drugs that temporarily boosted brain chemicals involved in memory and thinking. These medications, including combinations of memantine and donepezil, can improve thinking ability, behavior, or daily functioning in moderate to severe Alzheimer’s. They do not slow the disease itself. Symptoms may stabilize or improve for months, but the underlying brain damage continues. Side effects range from mild (nausea, constipation, decreased appetite) to serious but less common (seizures, slow heartbeat, trouble breathing).
The newer class of treatments works differently. These are antibody-based infusions designed to clear amyloid plaques, one of the two hallmark protein buildups in Alzheimer’s brains. The FDA has approved two of these drugs: lecanemab (sold as Leqembi) and donanemab (sold as Kisunla). Both target people in the early stages of the disease, specifically those with mild cognitive impairment or mild dementia who have confirmed amyloid buildup in their brains.
In clinical trials, lecanemab slowed cognitive decline by 27% over 18 months compared to a placebo. Donanemab showed statistically significant reductions in clinical decline across multiple measures at 76 weeks, including tests of cognition, daily functioning, and overall dementia severity. With donanemab, some patients cleared enough amyloid that they could stop treatment, a unique feature among current options.
These are real, measurable benefits, but they’re modest in practical terms. Slowing decline by roughly a quarter means the disease still progresses. A person taking these drugs will still lose memory and independence over time, just somewhat more slowly than they would without treatment.
Why Alzheimer’s Is So Hard to Cure
The full causes of Alzheimer’s remain unknown. The disease involves at least two types of abnormal protein buildup: amyloid plaques that accumulate between brain cells, and tau tangles that form inside them. Both lead to the death of neurons and the connections between them, and by the time symptoms appear, significant damage has already occurred. This is part of what makes a cure so elusive. You can’t regenerate neurons that are already gone.
The field has also learned that targeting amyloid alone isn’t enough. Clearing plaques helps, as the approved drugs demonstrate, but it doesn’t halt the disease. That’s driven researchers toward tau, the other major protein involved. Several therapies now in clinical testing aim to block the spread of misfolded tau from cell to cell, a process thought to drive much of the later-stage damage. These include antibody-based drugs designed to intercept tau before it can seed new tangles in healthy neurons, as well as a gene-silencing approach that reduces tau production at its source. None have reached approval yet.
Another complication is timing. Alzheimer’s biology begins years or even decades before the first noticeable symptoms. A major Phase 3 trial is testing donanemab in people with preclinical Alzheimer’s, those who show amyloid and tau changes on brain scans but have no cognitive symptoms yet. If intervening that early proves effective, it could redefine how the disease is managed, though results are still years away.
Getting Access to New Treatments
The newer anti-amyloid drugs come with significant practical hurdles. They’re administered as intravenous infusions, require regular brain scans to monitor for side effects (particularly brain swelling and microbleeds), and are expensive. Medicare covers lecanemab, but with conditions: you need a diagnosis of mild cognitive impairment or mild Alzheimer’s dementia, documented evidence of amyloid plaques in the brain, and a physician participating in a qualifying registry with an appropriate clinical team and follow-up plan. Even with coverage, the standard 20% coinsurance on a high-cost biologic adds up.
These treatments also aren’t an option for people with moderate or severe Alzheimer’s. The clinical trials studied them only in early-stage disease, and they’re approved accordingly. For the millions of people already in later stages, symptom-management drugs remain the primary option.
What Lifestyle Changes Actually Protect
One of the most encouraging findings in Alzheimer’s research has nothing to do with drugs. The FINGER trial, a landmark study out of Finland, tested a multi-domain lifestyle intervention combining exercise, cognitive training, nutritional guidance, and management of heart-health risk factors. Over two years, the intervention group showed 25% greater overall cognitive improvement than the control group. Some specific gains were striking: 83% greater improvement in executive function (planning, organizing, multitasking), 150% greater improvement in processing speed, and 40% greater improvement in complex memory tasks.
This doesn’t mean lifestyle changes cure or fully prevent Alzheimer’s. But they meaningfully reduce risk and improve cognitive resilience, particularly when started in midlife. The biggest modifiable risk factors include high blood pressure, physical inactivity, social isolation, hearing loss, diabetes, and smoking. Addressing these won’t guarantee you avoid the disease, but the evidence for their combined protective effect is strong enough that a global network of FINGER-style trials is now running in over 60 countries.
How Diagnosis Is Changing
Alzheimer’s is increasingly being redefined as a biological disease rather than a clinical one. Updated criteria from 2024 classify Alzheimer’s based on measurable biomarkers, specifically the presence of amyloid and tau changes in the brain, rather than waiting for symptoms to appear. Blood tests that detect these proteins are now part of the diagnostic framework, making earlier detection more feasible without requiring expensive brain scans for every patient.
This shift matters because earlier detection opens the window for treatments that work best before extensive brain damage has occurred. It also means more people may learn they have Alzheimer’s biology years before they would have been diagnosed under older criteria, raising difficult questions about what to do with that knowledge when treatment options remain limited. Still, for those eligible for the new anti-amyloid therapies, catching the disease early is the difference between qualifying for treatment and missing the window entirely.